AB Science SA
Fechado
0.86 -2.93
Visão Geral
Variação de preço das ações
24h
Mín
0.86
Máximo
0.915
Rendimento | 8.8M 3.6M |
|---|---|
Vendas | 144K 659K |
Margem de lucro | 549.317 |
Funcionários | 36 |
EBITDA | 1.8M -727K |
Capitalização de Mercado | -2.4M 66M |
|---|---|
Abertura anterior | 3.79 |
Fecho anterior | 0.86 |
AB Science SA Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
AB Science SA Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre AB Science SA
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
